Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans

Am J Clin Nutr. 2012 Jan;95(1):78-83. doi: 10.3945/ajcn.111.021543. Epub 2011 Dec 7.

Abstract

Background: Macronutrient "preloads" can stimulate glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), slow gastric emptying, and reduce postprandial glycemic excursions. After sweet preloads, these effects may be signaled by sodium-glucose cotransporter-1 (SGLT1), sweet taste receptors, or both.

Objective: We determined the effects of 4 sweet preloads on GIP and GLP-1 release, gastric emptying, and postprandial glycemia.

Design: Ten healthy subjects were studied on 4 separate occasions each. A preload drink containing 40 g glucose, 40 g tagatose/isomalt mixture (TIM), 40 g 3-O-methylglucose (3OMG; a nonmetabolized substrate of SGLT1), or 60 mg sucralose was consumed 15 min before a (13)C-octanoic acid-labeled mashed potato meal. Blood glucose, plasma total GLP-1 and GIP, serum insulin, and gastric emptying were determined.

Results: Both glucose and 3OMG stimulated GLP-1 and GIP release in advance of the meal (each P < 0.05), whereas TIM and sucralose did not. The overall postprandial GLP-1 response was greater after glucose, 3OMG, and TIM than after sucralose (P < 0.05), albeit later after TIM than the other preloads. The blood glucose and insulin responses in the first 30 min after the meal were greatest after glucose (each P < 0.05). Gastric emptying was slower after both 3OMG and TIM than after sucralose (each P < 0.05).

Conclusions: In healthy humans, SGLT1 substrates stimulate GLP-1 and GIP and slow gastric emptying, regardless of whether they are metabolized, whereas the artificial sweetener sucralose does not. Poorly absorbed sweet tastants (TIM), which probably expose a greater length of gut to nutrients, result in delayed GLP-1 secretion but not in delayed GIP release. These observations have the potential to optimize the use of preloads for glycemic control. This trial was registered at www.actr.org.au as ACTRN12611000775910.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Glucose / metabolism*
  • Dietary Sucrose / administration & dosage
  • Dietary Sucrose / pharmacology*
  • Disaccharides / pharmacology
  • Female
  • Gastric Emptying / drug effects*
  • Gastric Inhibitory Polypeptide / metabolism*
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucose / pharmacology
  • Hexoses / pharmacology
  • Humans
  • Incretins / metabolism*
  • Insulin / metabolism
  • Male
  • Postprandial Period
  • Signal Transduction / drug effects
  • Sodium-Glucose Transporter 1 / metabolism
  • Sucrose / analogs & derivatives
  • Sucrose / pharmacology
  • Sugar Alcohols / pharmacology
  • Sweetening Agents / administration & dosage
  • Sweetening Agents / pharmacology*
  • Young Adult

Substances

  • Blood Glucose
  • Dietary Sucrose
  • Disaccharides
  • Hexoses
  • Incretins
  • Insulin
  • SLC5A1 protein, human
  • Sodium-Glucose Transporter 1
  • Sugar Alcohols
  • Sweetening Agents
  • Sucrose
  • Gastric Inhibitory Polypeptide
  • Palatinit
  • Glucagon-Like Peptide 1
  • trichlorosucrose
  • Glucose
  • tagatose